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eligible, and 141 declined to participate. Thus, the final sample comprised 237 patients, 120 in the intervention group and 117 in the control group. In terms of age, the intervention group comprised 30.1% in the age class 22 -53 years, 20.9% in the age class 54 -64 years, 21.8% in the age class 64 -73, and 26.4% in the age class 74 years or older. The control group comprised 21.4% in the age class 22 -53 years, 27.7% in the age class 54 -64 years, 28.6% in the age class 64 -73, and 22.3% in the age class 74 years or older. The proportion of women was 60.9% in the intervention group and 57.1% in the control group. The demographics of patients who declined to participate were not available.
Study design
This was a prospective, randomised controlled trial, which was carried out in five general practices in the area of Nottinghamshire. Randomisation was based on computer-generated envelopes in permuted blocks (block size: 4) according to eight permutations of three criteria (age, gender and NSAID dose). The patients were followed for 6 months after randomisation, and the outcomes were assessed at baseline, 6 weeks and 6 months. Eight patients in the intervention group and 7 patients in the control group were lost to follow-up due to withdrawal. The patients were unaware of the study objectives, but the nurses were not blind to patient allocation. Thus, self-reported data were used to reduce potential assessment bias.
Analysis of effectiveness
The basis of the analysis of the clinical study is likely to have been intention to treat because the authors stated that data from withdrawn patients were included in the analysis whenever possible. The primary outcome measure used in the effectiveness study was the change in self-reported reduction in oral NSAID use after 6 months. The secondary outcome measures were changes in pain, physical functioning, utility, health status and quality-adjusted life-years (QALYs). These were estimated using the Short-Form 36, a visual analogue scale and EuroQol-5D. The authors stated that the two groups were comparable at baseline and the randomisation process was carried out successfully. A regression analysis was conducted to identify factors affecting the changes in the outcome measures.
Effectiveness results

NSAID use was:
stopped in 29% of the intervention patients and 11% of the control patients;
reduced by 50 to 99% in 9% (intervention) and 2% (control) of the patients, respectively; reduced by 25 to 49% in 4% (intervention) and 6% (control) of the patients, respectively; reduced by less than 25% or unchanged in 54% (intervention) and 79% (control) of the patients, respectively; and increased in 4% (intervention) and 3% (control) of the patients.
The differences in the percentages between the groups were statistically significant.
Higher initial NSAID prescription costs, patients aged 69 -79 years, and patients from practices associated with higher NSAID prescribing costs were factors associated with patients reducing their NSAID dose by more than 50%.
The changes in the remaining measures of health status, well-being and QALYs were generally not statistically different between the two groups. The exceptions were utility scores, which deteriorated significantly in the intervention group, and QALYs, which decreased in the intervention group while increasing in the control group. However, the regression analysis showed the lack of a relationship between this worse data and the lower use of NSAIDs.
Clinical conclusions
The effectiveness analysis showed that the nurse-delivered intervention was effective in reducing drug use in comparison with standard care, without significantly affecting the patients' health and quality of life.
